Can You Get GLP-1 If You Only Need to Lose 20-30 Pounds?

GLP-1 weight loss medications are heavily associated with significant obesity. But plenty of people with less to lose — 20, 25, 30 pounds — want access. Here is what the actual approval criteria say, and what your real options are.

The Official Approval Criteria

The FDA-approved indications for GLP-1 medications used for weight management are:

• Wegovy (semaglutide): BMI 30 or higher, or BMI 27–29.9 with at least one weight-related comorbidity (hypertension, type 2 diabetes, hyperlipidemia, sleep apnea)
• Zepbound (tirzepatide): Same criteria as Wegovy
• Ozempic (semaglutide): Approved for type 2 diabetes, not weight loss — though widely prescribed off-label for weight management

Whether a 20–30 pound goal puts you in those categories depends on your height and baseline weight. A 5'4" woman at 175 pounds has a BMI of 30.1 and officially qualifies. A 5'10" man at 190 pounds has a BMI of 27.3 — he would need a qualifying condition to access these medications through insurance.

What "BMI 27+ with a Comorbidity" Actually Covers

The comorbidity criteria is broader than most people realize. Qualifying conditions include:

• Hypertension (even well-controlled)
• Prediabetes (A1C of 5.7–6.4%)
• High cholesterol / dyslipidemia
• Obstructive sleep apnea
• Cardiovascular disease
• Certain metabolic conditions

Prediabetes and mild hypertension are extremely common — roughly 38% of American adults have prediabetes, many undiagnosed. If you have had borderline fasting glucose or blood pressure readings, this may qualify you even at a BMI of 27–29. A physician who is current on the guidelines will consider this; some who aren't will apply stricter criteria.

Insurance Versus Out-of-Pocket: How the Math Changes

If you don't meet the formal criteria, you have two practical options:

Compounded Semaglutide (Cash Pay)

Compounded semaglutide — available through telehealth platforms — is prescribed off-label and is significantly less expensive than brand-name Wegovy or Ozempic. Typical cost through reputable platforms: $150–$350 per month. This route doesn't require insurance approval and is accessible to patients who don't meet the formal BMI criteria, provided a physician agrees to prescribe.

Note: FDA restrictions on compounded semaglutide have fluctuated. As of mid-2026, compounded semaglutide remains available through 503A compounding pharmacies, but this regulatory status should be verified with your provider.

Brand-Name Without Insurance

Wegovy without insurance is $1,300–$1,500 per month at retail. Eli Lilly's savings program can bring Zepbound to $550/month for cash-pay patients. These prices make the brand-name route impractical for most people with small weight loss goals.

What to Realistically Expect at Lower Doses

GLP-1 medications are dose-dependent. Patients who don't need to lose large amounts of weight often do well at lower maintenance doses (0.5–1 mg semaglutide, or 2.5–5 mg tirzepatide) and may not need to titrate to the maximum doses studied in obesity trials. This also means lower side effect burden and potentially lower cost if dosed appropriately.

For a person losing 20–30 pounds over 6 months, the realistic outcome at appropriate doses is losing 10–15% of starting body weight — which may overshoot the goal. Providers who are thoughtful about this will plan for a lower maintenance dose or periodic use rather than continuous high-dose treatment.

Asking Your Doctor: How to Have the Conversation

If you have a weight loss goal in the 20–30 pound range and want to explore GLP-1 options, the most productive framing is around metabolic health, not just aesthetics:

• Get your fasting glucose and A1C tested if you haven't recently — prediabetes opens the door
• Check your blood pressure — borderline hypertension is a qualifying condition
• Come prepared with your specific goals, not just a number on the scale
• Ask about lower-dose options or compounded alternatives if cost is a concern

Frequently Asked Questions